130 related articles for article (PubMed ID: 27389555)
21. Direct detection of herceptin/trastuzumab binding on breast tissue sections.
Glazyrin A; Shen X; Blanc V; Eliason JF
J Histochem Cytochem; 2007 Jan; 55(1):25-33. PubMed ID: 16957165
[TBL] [Abstract][Full Text] [Related]
22. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
23. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
[TBL] [Abstract][Full Text] [Related]
24. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
25. Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: comparison of immunohistochemistry and multiparameter DNA flow cytometry.
Leers MP; Hoop JG; Nap M
Anticancer Res; 2003; 23(2A):999-1006. PubMed ID: 12820338
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
27. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
28. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection.
Li Y; Zhang R; Han Y; Lu T; Ding J; Zhang K; Lin G; Xie J; Li J
Diagn Pathol; 2016 Sep; 11(1):85. PubMed ID: 27613595
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
Recupero D; Daniele L; Marchiò C; Molinaro L; Castellano I; Cassoni P; Righi A; Montemurro F; Sismondi P; Biglia N; Viale G; Risio M; Sapino A
J Pathol; 2013 Feb; 229(3):390-9. PubMed ID: 22806884
[TBL] [Abstract][Full Text] [Related]
31. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples.
Wang HY; Kim S; Park S; Kim S; Jung D; Park KH; Lee H
Exp Mol Pathol; 2014 Dec; 97(3):368-74. PubMed ID: 25236569
[TBL] [Abstract][Full Text] [Related]
33. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
34. Usefulness and efficiency of formalin-fixed paraffin-embedded specimens from laryngeal squamous cell carcinoma in HPV detection by IHC and PCR/DEIA.
Morshed K; Polz-Dacewicz M; Szymański M; Smoleń A
Folia Histochem Cytobiol; 2010 Sep; 48(3):398-402. PubMed ID: 21071345
[TBL] [Abstract][Full Text] [Related]
35. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
Müller BM; Kronenwett R; Hennig G; Euting H; Weber K; Bohmann K; Weichert W; Altmann G; Roth C; Winzer KJ; Kristiansen G; Petry C; Dietel M; Denkert C
Diagn Mol Pathol; 2011 Mar; 20(1):1-10. PubMed ID: 21326033
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.
Dębska-Szmich S; Kusińska R; Czernek U; Szydłowska-Pazera K; Habib-Lisik M; Piekarski JH; Olas E; Kulig A; Ułańska M; Kalinka-Warzocha E; Potemski P
Postepy Hig Med Dosw (Online); 2015 May; 69():586-97. PubMed ID: 25983297
[TBL] [Abstract][Full Text] [Related]
37. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M
Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811
[TBL] [Abstract][Full Text] [Related]
38. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.
Hembrough T; Thyparambil S; Liao WL; Darfler MM; Abdo J; Bengali KM; Hewitt SM; Bender RA; Krizman DB; Burrows J
J Mol Diagn; 2013 Jul; 15(4):454-65. PubMed ID: 23672976
[TBL] [Abstract][Full Text] [Related]
39. Droplet Digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples.
Heredia NJ; Belgrader P; Wang S; Koehler R; Regan J; Cosman AM; Saxonov S; Hindson B; Tanner SC; Brown AS; Karlin-Neumann G
Methods; 2013 Jan; 59(1):S20-3. PubMed ID: 23036330
[TBL] [Abstract][Full Text] [Related]
40. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
